Cardiff Oncology (CRDF) Non-Current Deffered Revenue (2016 - 2018)

Cardiff Oncology has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $1.1 million in Q4 2018.

• Quarterly Non-Current Deffered Revenue fell 7.86% year-over-year to $1.1 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.1 million (down 7.86% YoY) and the FY2018 annual result came in at $1.1 million, down 7.86% from the prior year.
• Non-Current Deffered Revenue declined to $1.1 million in Q4 2018 per CRDF's latest filing, from $1.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $1.4 million in Q3 2016 and troughed at $1.0 million in Q2 2018.
• A 3-year average of $1.2 million and a median of $1.2 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue fell 20.29% in 2017, then advanced 4.4% in 2018.
• Over 3 years, Non-Current Deffered Revenue stood at $1.4 million in 2016, then slipped by 13.83% to $1.2 million in 2017, then declined by 7.86% to $1.1 million in 2018.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1.1 million, $1.2 million, and $1.0 million for Q4 2018, Q3 2018, and Q2 2018 respectively.